rs371970388
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_032119.4(ADGRV1):c.13228G>A(p.Glu4410Lys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000117 in 1,600,272 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_032119.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ADGRV1 | ENST00000405460.9 | c.13228G>A | p.Glu4410Lys | missense_variant | 65/90 | 1 | NM_032119.4 | ENSP00000384582.2 | ||
ADGRV1 | ENST00000638510.1 | n.495G>A | non_coding_transcript_exon_variant | 1/26 | 1 | |||||
ADGRV1 | ENST00000425867.3 | c.2182G>A | p.Glu728Lys | missense_variant | 13/38 | 5 | ENSP00000392618.3 | |||
ADGRV1 | ENST00000639431.1 | n.265+105366G>A | intron_variant | 5 | ENSP00000491057.1 |
Frequencies
GnomAD3 genomes AF: 0.0000657 AC: 10AN: 152110Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000618 AC: 15AN: 242614Hom.: 0 AF XY: 0.0000304 AC XY: 4AN XY: 131364
GnomAD4 exome AF: 0.000123 AC: 178AN: 1448162Hom.: 0 Cov.: 30 AF XY: 0.000114 AC XY: 82AN XY: 717992
GnomAD4 genome AF: 0.0000657 AC: 10AN: 152110Hom.: 0 Cov.: 32 AF XY: 0.0000673 AC XY: 5AN XY: 74306
ClinVar
Submissions by phenotype
not provided Uncertain:2Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Aug 04, 2023 | Observed with the G2756R variant in the ADGRV1 gene in a patient with myoclonic epilepsy in published literature (Myers et al., 2018); Observed with the G2756R variant in the ADGRV1 gene in unrelated patients referred for genetic testing at GeneDx, confirmed to be on the same allele (in cis) in a single case; In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 29266188, 34160719, 36399868, 32962041) - |
Uncertain significance, criteria provided, single submitter | clinical testing | Athena Diagnostics | Dec 06, 2024 | Available data are insufficient to determine the clinical significance of the variant at this time. The frequency of this variant in the general population is uninformative in assessment of its pathogenicity. (http://gnomad.broadinstitute.org) Polyphen and MutationTaster predict this amino acid change may be benign. - |
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 24, 2023 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Feb 28, 2017 | Variant classified as Uncertain Significance - Favor Benign. The p.Glu4410Lys va riant in GPR98 has not been previously reported in individuals with Usher syndro me, but has been identified in 3/61466 European chromosomes by the Exome Aggrega tion Consortium (ExAC, http://exac.broadinstitute.org; dbSNP rs371970388). Altho ugh this variant has been seen in the general population, its frequency is not h igh enough to rule out a pathogenic role. The glutamic acid (Glu) at position 44 10 is not conserved across species with two mammals (squirrel and aardvark) havi ng a lysine (Lys) at this position despite high nearby amino acid conservation. In addition, computational prediction tools do not suggest a high likelihood of impact to the protein. In summary, while the clinical significance of the p.Glu4 410Lys variant is uncertain, available data suggest that it is more likely to be benign. - |
Usher syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | May 26, 2020 | Based on the classification scheme VCGS_Germline_v0.6.1, this variant is classified as a 3C-VUS. Following criteria are met: 0102 - Loss of function is a known mechanism of disease for this gene. 0108 - This gene is known to be associated with both recessive and dominant disease. 0200 - Variant is predicted to result in a missense amino acid change from a glutamic acid to a lysine (exon 65). 0304 - Variant is present in gnomAD <0.01 for recessive indication (18 heterozygotes, 0 homozygotes) 0309 - An alternative amino acid change at the same position has been observed in gnomAD (1 heterozygote, 0 homozygotes). 0503 - Missense variant consistently predicted to be tolerated OR not conserved in mammals with a minor amino acid change. 0600 - Variant is located in an annotated domain or motif that does not have a well-established function (Calx-beta domain). 0705 - No comparable variants in relevant codon/region have previous evidence for pathogenicity. 0807 - Variant has not previously been reported in a clinical context. 0905 - No published segregation evidence has been identified for this variant. 1007 - No published functional evidence has been identified for this variant. Legend: (P) - Pathogenic, (N) - Neutral, (B) - Benign - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at